Insulin aspart: A review of its use in the management of type 1 or 2 diabetes mellitus

Drugs

Volumn 64, Issue 17, 2004, Pages 1957-1974

  Reynolds, Neil A ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE;

BOLUS INJECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG TOLERABILITY; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUNGER; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREMOR;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; CLINICAL TRIALS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; QUALITY OF LIFE;

EID: 4644360094     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464170-00013     Document Type: Review

References (63)

1. World Health Organisation. Diabetes (WHO global strategy on diet, physical activity and health) [online]. Available from URL: http://www.who.int/ dietphysicalactivity/publications/facts/diabetes/en/ [Accessed 2004 Jun 8 ]
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329 (14): 977-86
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352: 837-53
4. Stratton IM, Adler AI, Neil HAW, et al., on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321: 405-12
5. American Diabetes Association. 2004 Clinical Practice Recommendations. Diabetes Care 2004 Jan; 27 Suppl. 1: S1-143
6. Gummerson I. Insulin analogues revisited. Hosp Pharmacist 2003 Apr; 10 (4): 165-7, 169-73
7. Haycox A. Insulin aspart: a comprehensive evidence-based medicine review. Clin Drug Invest. In press
8. Gammeltoft S, Hansen BF, Dideriksen L, et al. Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opin Invest Drugs 1999; 8 (9): 1431-41
9. Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 2003 Jan; 26 (1): 183-6
10. Umpierrez GE, Cuervo R, Karabell A, et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004; 28 (8): 1873-8
11. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002; 62 (13): 1945-81
12. Kaku K, Matsuda M, Urae A, et al. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 2000 Aug; 49 (2-3): 119-26
13. Nosek L, Heinemann L, Kaiser M, et al. No increase in the duration of action with rising doses of insulin aspart [abstract no. 551-P]. Diabetes 2003 Jun; 52 Suppl. 1: A128-9
14. Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998 Nov; 21 (11): 1910-4
15. Perriello G, Avogaro A, Emanuele B, et al. Superior meal-time glucose control with insulin aspart (NovoLog®) compared with human insulin in both normal-weight and overweight people with type 2 diabetes: a randomized, stratified, double-blind, crossover trial [abstract no. 452-P]. Diabetes 2002 Jun; 51 Suppl. 2: A111
16. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999 May; 22 (5): 801-5
17. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000 Mar; 37 (1): 41-6
18. Home PD, Lindholm A, Hylleberg B, et al., for the U.K. Insulin Aspart Study Group. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998 Nov; 21 (11): 1904-9
19. Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002 Nov; 25 (11): 2053-7
20. Homko C, Deluzio A, Jimenez C, et al. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003 Jul; 26 (7): 2027-31
21. DeVries JH, Lindholm A, Jacobsen JL, et al., on behalf of the Tri-Continental Insulin Aspart Study Group. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1 diabetes. Diabet Med 2003 Apr; 20 (4): 312-8
22. Home PD, Lindholm A, Riis A, for the European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000 Nov; 17 (11): 762-70
23. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000 May; 23 (5): 583-8
24. Tamás G, Marre M, Astorga R, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001 Nov; 54 (2): 105-14
25. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004 May; 27 (5): 1081-7
26. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basalbolus therapy for patients with type 1 diabetes. Diabetologia 2004 Mar 12; 47: 622-9
27. Bretzel RG, Arnolds S, Medding J, et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004 May; 27 (5): 1023-7
28. McGill J, Raskin P, Kilo C, et al. Human insulin analog, insulin aspart, is a mealtime insulin comparable to human insulin in type 2 diabetes [abstract no. 894]. Diabetologia 1999 Aug; 42 Suppl. 1: A238
29. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002 Mar; 25 (3): 439-44
30. DeVries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycaemic control. Diabetes Care 2002 Nov; 25 (11): 2074-80
31. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003 Sep; 26 (9): 2598-603
32. Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000 May; 17 (5): 371-5
33. Mortensen HB, Lindholm A, Olsen BS, et al. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000 Jul; 159 (7): 483-8
34. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004 Jul; 27 (7): 1554-8
35. Danne T, Aman J, Schober E, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003 Aug; 26 (8): 2359-64
36. Krones R, Heise T, Basir S, et al. Time-action profiles of insulin aspart and human regular insulin in elderly and middle-aged subjects with type 2 diabetes [abstract no. 560-P]. Diabetes 2004 Jun; 53 Suppl. 2: A133
37. Gallagher A, Home PD. The effect of insulin aspart on post-prandial metabolism and lipid profile in type 2 diabetes [abstract no. 788]. Diabetologia 2002 Aug; 45 Suppl. 2: A253-4
38. Hamilton-Wessler M, Buchanan T, Hathout E, et al. Time-action profile for intravenously infused insulin aspart and insulin lispro in type 1 diabetic subjects [abstract no. 403-P]. Diabetes 2002 Jun; 51 Suppl. 2: A99
39. Novo Nordisk Limited. NovoRapid: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Apr 27]
40. Novo Nordisk Pharmaceuticals Inc. NovoLog®: insulin aspart (rDNA origin) injection. Prescribing information [online]. Available from URL: http://www.novolog.com [Accessed 2004 May 5]
41. Lindholm A, Sasaki T, Edwards A, et al. Dose dependency in absorption of insulin aspart in healthy Caucasians and Japanese [abstract no. 1840-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A441
42. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001; 40 (9): 641-59
43. von Mach M-A, Brinkmann C, Hansen T, et al. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2002 Nov; 110 (8): 416-9
44. Lindström T, Hedman CA, Arnqvist HJ. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs. Diabetes Care 2002 Jun; 25 (6): 1049-54
45. Plum A, Larsen PS, Larsen UD, et al. Determination of in vitro plasma protein binding of insulin aspart and insulin detemir by equilibrium dialysis [abstract no. 886]. Diabetologica 1999; 42 Suppl. 1: A236
46. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999 May; 55 (3): 199-203
47. Robinson RTCE, Harris ND, Ireland RH, et al. Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization. Br J Clin Pharmacol 2003 Mar; 55 (3): 246-51
48. Hedman CA, Lindstrom T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes [letter]. Diabetes Care 2001 Jun; 24 (6): 1120-1
49. Lyness W, Tyler J, Lawrence A. Pharmacokinetics of the rapid-acting insulin-analog, insulin aspart, is independent of hepatic function [abstract no. 1843-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A442
50. Lyness W, Tyler JF, Lawrence A. Renal impairment does not affect insulin aspart pharmacokinetics in type 1 diabetes [abstract no. 1842-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A441-2
51. Lyness W, Tyler J, Lawrence A. BMI does not affect insulin aspart pharmacokinetics in type I diabetes [abstract no. 499-P]. Diabetes 2001 Jun; 50 Suppl. 2: A124
52. Tsalikian E. Insulin aspart in pediatric and adolescent patients with type 1 diabetes [abstract no. 767]. Diabetologia 2000 Aug; 43 Suppl. 1: 200
53. Poulsen MK, Henriksen JE, Hother-Nielsen O, et al. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003 Dec; 26 (12): 3273-9
54. de Boer H., Jansen M, Koerts J, et al. Prevention of weight gain in type 2 diabetes requiring insulin treatment. Diabetes Obes Metab 2004 Mar; 6 (2): 114-9
55. Amiel S, Home PD, Jacobsen JL, et al. Insulin aspart safe for long-term treatment [abstract no. 802]. Diabetologia 2001; 44 Suppl. 1: A209
56. Bott U, Ebrahim S, Hirschberger S, et al. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003 Aug; 20 (8): 626-34
57. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004 Jul; 21 (7): 769-75
58. Lindholm A, Jensen LB, Home PD, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002 May; 25 (5): 876-82
59. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-30
60. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med 2002 Sep; 113 (4): 308-16
61. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002 Jun; 16 (3): 475-92
62. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc 2003; 78 (4): 459-67
63. McIntosh A, Hutchinson A, Home PD, et al. Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose [online]. Available from URL: http://www.shef.ac.uk/guidelines/ [Accessed 2004 Jun 16]